Antiepileptic drug interactions in children

Antiepileptic Drugs: Combination Therapy and Interactions

Volumn , Issue , 2005, Pages 257-272

  Dulac, Olivier ^a   Rey, Elizabeth ^b   Chiron, Catherine ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891549177     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545023.016     Document Type: Chapter

References (79)

1. Aicardi J. Clinical approach to the management of intractable epilepsy. Dev Med Child Neurol 1988; 30: 429–440.
2. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 1167–1178.
3. Ambrosetto G, Tassinari CA. Antiepileptic drug treatment of benign childhood epilepsy with rolandic spikes: is it necessary? Epilepsia 1990; 31: 802–805.
4. Appleton RE, Peters AC, Mumford JP, et al. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999; 40: 1627–1633.
5. Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study. Dev Med Child Neurol 2001; 43: 269–273.
6. Baciewicz AM, Baciewicz Jr FA. Cyclosporine pharmacokinetic drug interactions. Am J Surg 1989; 157: 264–271.
7. Battaglia D, Iuvone L, Stefanini MC, et al. Reversible aphasic disorder induced by lamotrigine in atypical benign childhood epilepsy. Epileptic Disord 2001; 3: 217–222.
8. Besag FM, Wallace SJ, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991–997.
9. Bourgeois BF. Problems of combination drug therapy in children. Epilepsia 1988; 29(Suppl. 3): S20–S24.
10. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997; 26: 423–32.
11. Bryant III AE, Dreifuss FE. Valproic acid hepatic fatalities. III. U. S. experience since 1986. Neurology 1996; 46: 465–469.
12. Cadle RM, Zenon III GJ, Rodriguez-Barradas MC, et al. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994; 28: 191–195.
13. Casse-Perrot C, Wolf P, Dravet C. Neuropsychological aspects of severe myoclonic epilepsy in infancy. In I. Jambaque, M. Lassonde, O. Dulac, eds. Neuropsychology of Childhood Epilepsy. New York: Kluwer Academic/Plenum Press, 2001: 131–140.
14. Chaigne D, Dulac O. Carbamazepine versus valproate in partial epilepsies of childhood. Advances in Epileptology. New York: Raven Press, 2003: 17.
15. Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26: 389–395.
16. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356: 1638–1642.
17. Cianchetti C, Pruna D, Coppola G, et al. Low-dose lamotrigine in West syndrome. Epilepsy Res 2002; 51: 199–200.
18. Cooney GF, Mochon M, Kaiser B, et al. Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. Pharmacotherapy 1995; 15: 353–356.
19. Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 2002; 49: 45–48.
20. Corda D, Gelisse P, Genton P, et al. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia 2001; 42: 754–759.
21. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982; 23: 693–720.
22. Deckers CL, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42: 1387–1394.
23. Dooley JM, Camfield PR, Smith E, et al. Topiramate in intractable childhood onset epilepsy – a cautionary note. Can J Neurol Sci 1999; 26: 271–273.
24. Douidar SM, Ahmed AE. A novel mechanism for the enhancement of acetaminophen hepatotoxicity by phenobarbital. J Pharmacol Exp Ther 1987; 240: 578–583.
25. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379–385.
26. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989; 39: 201–217.
27. Dulac O, Steru D, Rey E, et al. Sodium valproate (Na VPa) monotherapy in childhood epilepsy. Arch Fr Pediatr 1982; 39: 347–352.
28. Dulac O, Plouin P, Shewmon A. Myoclonus and epilepsy in childhood: 1996 Royaumont meeting. Epilepsy Res 1998; 30: 91–106.
29. Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57: 1416–1421.
30. Facciola G, Avenoso A, Spina E, et al. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998; 20: 628–630.
31. Fridell JA, Jain AK, Patel K, et al. Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report. Ther Drug Monit 2003; 25: 117–119.
32. Gerber PE, Hamiwka L, Connolly MB, et al. Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. Pediatr Neurol 2000; 22: 200–203.
33. Glauser TA. Expanding first-line therapy options for children with partial seizures. Neurology 2000; 55: S30–S37.
34. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508–512.
35. Hussein G, Troupin AS, Montouris G. Gabapentin interaction with felbamate. Neurology 1996; 47: 1106.
36. Kaminska A, Ickowicz A, Plouin P, et al. Delineation of cryptogenic Lennox–Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis. Epilepsy Res 1999; 36: 15–29.
37. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New Engl J Med 2000; 342: 314–319.
38. Lane HY, Su KP, Chang WH, et al. Elevated plasma clozapine concentrations after phenobarbital discontinuation. J Clin Psychiatr 1998; 59: 131–133.
39. Langbehn DR, Alexander B. Increased risk of side-effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. Pharmacopsychiatry 2000; 33: 196.
40. Levy R, Loiseau P, Guyot A, et al. Effects of stiripentol on valproate plasma level and metabolism. Epilepsia 1987; 28(5): 605.
41. Lortie A, Chiron C, Mumford J, et al. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993; 43: S24–S27.
42. Loscher W, Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 1985; 24: 427–435.
43. Luna D, Dulac O, Pajot N, et al. Vigabatrin in the treatment of childhood epilepsies: a singleblind placebo-controlled study. Epilepsia 1989; 30: 430–437.
44. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175–181.
45. Mesdjian E, Dravet C, Cenraud B, et al. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia 1980; 21: 489–496.
46. Mikaeloff Y, Saint-Martin A, Mancini J, et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003; 53: 225–232.
47. Morselli PL, Principi N, Tognoni G, et al. Diazepam elimination in premature and full term infants, and children. J Perinat Med 1973; 1: 133–141.
48. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. New Engl J Med 1997; 337: 1807–1812.
49. Nau H, Loscher W, Schafer H. Anticonvulsant activity and embryotoxicity of valproic acid. Neurology 1984; 34: 400–401.
50. Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999; 40: 1618–1626.
51. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5–17.
52. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate–lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141–1146.
53. Rafi JA, Frazier LM, Driscoll-Bannister SM, et al. Effect of over-the-counter cimetidine on phenytoin concentrations in patients with seizures. Ann Pharmacother 1999; 33: 769–774.
54. Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia 2000; 41: 1284–1288.
55. Rey E, Bulteau C, Motte J, et al. Multicenter study of oxcarbazepine pharmacokinetics and long-term tolerability as open-label, add-on therapy in children with refractory epilepsy. J Clin Pharmacol 2004; 44: 1290–1300.
56. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981; 22: 1–10.
57. Ritter F, Glauser TA, Elterman RD, et al. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group. Epilepsia 2000; 41(Suppl. 1): S82–S85.
58. Roger J. Epileptic Syndromes in Infancy, Childhood and Adolescence. M. Bureau, C. Dravet, F. Dreifuss, A. Perret, P. Wolf, eds. London: John Libbey, 1992.
59. Rosche J, Froscher W, Abendroth D, et al. Possible oxcarbazepine interaction with cyclosporine serum levels: a single case study. Clin Neuropharmacol 2001; 24: 113–116.
60. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Topiramate YL Study Group. Neurology 1999; 52: 1882–1887.
61. Sallas WM, Milosavljev S, D’Souza J, et al. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 2003; 74: 138–149.
62. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32: 157–163.
63. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359–367.
64. Schoeman JF, Elyas AA, Brett EM, et al. Correlation between plasma carbamazepine-10, 11-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neurol 1984; 26: 756–764.
65. Serdaroglu G, Kurul S, Tutuncuoglu S, et al. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003; 28: 37–41.
66. Siegel H, Kelley K, Stertz B, et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox–Gastaut syndrome. Epilepsy Res 1999; 34: 91–97.
67. Talwar D, Arora MS, Sher PK. EEG changes and seizure exacerbation in young children treated with carbamazepine. Epilepsia 1994; 35: 1154–1159.
68. Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet’s syndrome). Arch Pediatr 2002; 9: 1120–1127.
69. Thompson PA, Mosley CA. Tacrolimus–phenytoin interaction. Ann Pharmacother 1996; 30: 544.
70. Tran A, Vauzelle-Kervroedan F, Rey E, et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol 1996; 50: 497–500.
71. Turnbull DM, Rawlins MD, Weightman D, et al. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatr 1982; 45: 55–59.
72. Ueberall MA. Normal growth during lamotrigine monotherapy in pediatric epilepsy patients – a prospective evaluation of 103 children and adolescents. Epilepsy Res 2001; 46: 63–67.
73. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2: 404–409.
74. Veggiotti P, Cieuta C, Rex E, et al. Lamotrigine in infantile spasms. Lancet 1994; 344: 1375–1376.
75. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995; 37: 97–108.
76. Villeneuve N, Soufflet C, Plouin P, et al. Treatment of infantile spasms with vigabatrin as first-line therapy and in monotherapy: apropos of 70 infants. Arch Pediatr 1998; 5: 731–738.
77. Vu VT, Bai SA, Abramson FP. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics. J Pharmacol Exp Ther 1983; 224: 55–61.
78. Wasfi IA, Tanira MO. The effect of chronic administration of cyclosporin A on phenytoin pharmacokinetic parameters in the rat. Life Sci 1993; 52: 199–204.
79. Yusof WZ. Gingival hyperplasia: an intra-oral side effect of phenytoin, nifedipine and cyclosporine therapies. Singapore Med J 1988; 29: 498–503.